Tibet Weixinkang Medicine Co Ltd

Weixinkang announced that its wholly-owned subsidiary Baiyi Pharmaceutical has received the Drug Registration Certificate for Water-Soluble Vitamins for Injection issued by the National Medical Products Administration. The specification is compound, the registration classification is chemical drug category 3, and it is deemed to have passed consistency evaluation. This drug is an indispensable component of parenteral nutrition, used to meet the daily physiological needs of adults and children for water-soluble vitamins. The announcement shows that the company's cumulative R&D investment is approximately 8.03 million yuan, unaudited. Weixinkang stated that it has begun pre-launch preparations, but future sales are subject to uncertainty due to factors such as the market environment and bidding.

Weixinkang's wholly-owned subsidiary Yangpu Jingtai has received the Drug Supplementary Application Approval Notice for Potassium Aspartate Injection issued by the National Medical Products Administration, approving the addition of a new specification of 20 milliliters, containing 3.424 grams of potassium aspartate, and deeming it to have passed the consistency evaluation. The drug is an electrolyte supplement used to treat hypokalemia caused by various reasons. According to data from Menet, in 2025 the drug's terminal sales in domestic urban public hospitals and county-level public hospitals amounted to 412 million yuan, and the company's cumulative research and development investment was approximately 1.2184 million yuan. Weixinkang stated that it has begun pre-launch preparations, but future sales are subject to uncertainties due to factors such as the market environment and bidding processes.

Weixinkang's wholly-owned subsidiary Baiyi Pharmaceutical has received the drug registration certificate for Multivitamin for Injection (12) approved and issued by the National Medical Products Administration. The product specification is 5 ml per vial, registered as a Category 4 chemical drug, and deemed to have passed the consistency evaluation. Multivitamin for Injection (12) is an intravenous vitamin supplement indicated for adult and pediatric patients aged 11 years and older who require vitamin supplementation via injection when oral nutrition is contraindicated, impossible, or insufficient.

Weixinkang's wholly-owned subsidiary Baiyi Pharmaceutical has received the Drug Registration Certificate for Compound Potassium Hydrogen Phosphate Injection issued by the National Medical Products Administration. The product specification is 5 ml containing 1.12 g of potassium dihydrogen phosphate and 1.18 g of dipotassium hydrogen phosphate, approved as a Category 3 chemical drug and deemed to have passed the consistency evaluation. Compound Potassium Hydrogen Phosphate Injection is indicated for the correction of hypophosphatemia and parenteral nutrition support in adults and children. The original reference listed drug is not marketed in China.